Characteristics | TEAS group (n = 362) | Control group (n = 369) | P |
---|---|---|---|
Age, years (mean ± SD) | 31.5 ± 4.4 | 31.7 ± 4.7 | 0.749 |
Race, n (%) | Â | Â | 0.317 |
  Han | 345 (95.3) | 357 (96.8) |  |
  Minorities | 17 (4.7) | 12 (3.3) |  |
BMI, kg/m2 (mean ± SD) | 22.5 ± 3.0 | 22.4 ± 3.1 | 0.556 |
Drinking history, n (%) | 360 (99.5) | 368 (99.7) | 0.621 |
Years of infertility (years) | 3 (2,6) | 4 (2,6) | 0.579 |
History of acupuncture, n (%) | 15 (4.1) | 10 (2.7) | 0.289 |
Times of IVF-ET, n (%) | Â | Â | 0.423 |
  1 | 185 (51.1) | 196 (53.1) |  |
  2–3 | 175 (48.3) | 168 (45.5) |  |
  ≥ 4 | 2 (0.6) | 5 (1.4) |  |
Causes of infertility, n (%) | Â | Â | 0.824 |
  Gamete transport disorders | 333 (92.0) | 341 (92.4) |  |
  Ovulation dysfunction | 18 (5.0) | 14 (3.8) |  |
  Endometriosis | 6 (1.7) | 8 (2.2) |  |
  Immunological infertility | 5 (1.4) | 6 (1.6) |  |
Embryo, n (%) | Â | Â | 0.771 |
  Fresh | 183 (50.6) | 190 (51.6) |  |
  Cryopreserved | 179 (49.5) | 178 (48.4) |  |
Comorbidities (before treatment), n (%) | Â | Â | 0.953 |
  Hyperlipemia | 2 (0.6) | 0 |  |
  Hyperprolactinemia | 2 (0.6) | 3 (0.8) |  |
  Hyperthyroidism | 1 (0.3) | 1 (0.3) |  |
  Subhypothyroidism | 2 (0.6) | 2 (0.5) |  |
  Hypothyroidism | 3 (0.8) | 1 (0.3) |  |
Uterine cavity lesions, n (%) | Â | Â | 0.833 |
  Submucous myoma | 8 (2.2) | 11 (3.0) |  |
  Uterine mediastinum | 2 (0.6) | 0 |  |
Thin endometrium due to repeated curettages | 1 (0.3) | 3 (0.8) | Â |
Drugs, n (%) | |||
  Combined drug therapy after inclusion | 122 (33.7) | 125 (33.9) | 0.938 |
  Continue drug therapy after inclusion | 24 (6.6) | 34 (9.2) | 0.219 |